Peptor: Taking a SCAPL to large molecules

While large peptides and proteins are essential to normal body functions, their limitations as drug candidates have been well documented. To overcome those limits, Peptor is using combinatorial chemistry to develop anti-inflammatory drugs based on its SCAPL platform technology.

SCAPLs (small cyclic analogs of peptide loops) comprise the biologically active parts of large proteins and peptides. According to Peptor, they have shown higher specificity for the molecules involved in disease, improved metabolic stability and the possibility of oral delivery. In addition, Peptor's approach is designed to optimize SCAPLs as drug candidates prior to synthesis, thus offering a more efficient method of drug discovery than current techniques that often rely on optimization after synthesis...